Biopharma Co Vyome gets Rs 154 crore from investors

New Delhi: Vyome Therapeutics, a biopharmaceutical firm focused on developing dermatology products, has raised $22 million (about Rs 154 crore) in a fresh round of funding led by Mumbai based venture growth fund Iron Pillar to expand its team and further invest in research and development.

Existing investors Perceptive Advisors, Romulus Capital and Kalaari Capital also participated in this round. Part of the funds are being used for a secondary transaction, the company said without elaborating. Prior to this round, the company had raised about $30 million from Perceptive Advisors, Romulus Capital, Kalaari Capital, Sabre Partners India, Aarin Capital and Navam Capital.

Dermatological conditions are among the most common types of disorders globally and a majority of the market share is held by large pharmaceutical firms with established product lines. However, with the emergence of a number of startups which have proven clinical and commercial success along with d eep understanding of many dermatological conditions, there is a renewed investor interest in disruptive companies in this segment.

  • Related Posts

    Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

    With heroin availability falling, Punjab Police claims the pattern of drug consumption and supply is changing. Pharmaceutical narcotics have now emerged as the state’s biggest drug enforcement challenge. Chandigarh: The…

    Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

    Bengaluru: In a major breakthrough in the illegal pharmaceutical network operating in Karnataka, investigators from the Special Investigation Team (SIT) raided Krupa Health Care at Minerva Circle, seizing a cache…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

    Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

    Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

    Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

    Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

    Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

    Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit